Sepsis Biomarkers in Polytrauma Patients

Critical Care Clinics

Volumn 27, Issue 2, 2011, Pages 345-354

  Adams, Charles A ^a,b  

^a BROWN UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

Author keywords

Biomarker; Sepsis; Trauma

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANNEXIN; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CATHELICIDIN; CYTOKINE; DEFENSIN; EOSINOPHIL PROTEIN X; HEAT SHOCK PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; LITHOSTATHINE; NATRIURETIC PEPTIDE TYPE C; PROCALCITONIN; PROTEIN S 100;

BACTEREMIA; BACTERIAL INFECTION; CALCIUM HOMEOSTASIS; CD4+ CD25+ T LYMPHOCYTE; COMORBIDITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE PREDISPOSITION; DISEASE SEVERITY; ENDOTHELIAL PROGENITOR CELL; ENDOTOXEMIA; GENE EXPRESSION; HEMORRHAGIC SHOCK; HUMAN; INJURY SEVERITY; MORTALITY; MULTIPLE ORGAN FAILURE; MULTIPLE TRAUMA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN LOCALIZATION; REVIEW; SENSITIVITY AND SPECIFICITY; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

BIOLOGICAL MARKERS; HUMANS; MULTIPLE TRAUMA; SEPSIS; TRAUMA SEVERITY INDICES;

EID: 79953011090     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccc.2010.12.002     Document Type: Review

References (78)

1. Available at:, Accessed November 12, 2010. http://www.cdc.gov/Injury/Publications/FactBook.
2. Baker C.C., Oppenheimer L., Stephens B., et al. Epidemiology of trauma deaths. Am J Surg 1980, 140:144-150.
3. Trunkey D.D. Trauma. Accidental and intentional injuries account for more years of life lost in the U.S. than cancer and heart disease. Among the prescribed remedies are improved preventive efforts, speedier surgery and further research. Sci Am 1983, 249:28-35.
4. The Biomarker Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95.
5. Ventetuolo C.E., Levy M.M. Biomarkers: diagnosis and risk assessment in sepsis. Clin Chest Med 2008, 29:591-603.
6. Lenz A., Franklin G.A., Cheadle W.A. Systemic inflammation after trauma. Injury 2007, 38:1336-1345.
7. Keel M., Trentz O. Pathophysiology of polytrauma. Injury 2005, 36:691-709.
8. Hauser C.J., Zhou X., Joshi P., et al. The immune microenvironment of human fracture/soft-tissue hematomas and its relationship to systemic immunity. J Trauma 1997, 42:895-903.
9. Maier B., Lefering R., Lehnert M., et al. Early versus late onset of multiple organ failure is associated with differing patterns of plasma cytokine biomarker expression and outcome after severe trauma. Shock 2007, 28:668-674.
10. Morganti-Kosmann M.C., Rancan M., Otto V.I., et al. Role of cerebral inflammation after traumatic brain injury: a revised concept. Shock 2001, 16:165-177.
11. Strecker W., Gebhard F., Rager J., et al. Early biochemical characterization of soft-tissue trauma and fracture trauma. J Trauma 1999, 47:358-364.
12. Roumen R.M., Redl H., Schlag G., et al. Inflammatory mediators in relation to the development of multiple organ failure in patients after severe blunt trauma. Crit Care Med 1995, 23:474-480.
13. Roumen R.M., Hendriks T., van der Ven-Jongekrijg J., et al. Cytokine patterns in patients after major vascular surgery, hemorrhagic shock, and severe blunt trauma. Relationship with subsequent adult respiratory distress syndrome and multiple organ failure. Am Surg 1993, 218:769-776.
14. Maier B., Schwerdtfeger K., Mautes A., et al. Differential release of interleukins 6, 8, and 10 in cerebrospinal fluid and plasma after traumatic brain injury. Shock 2001, 15:421-426.
15. Lausevic Z., Lausevic M., Trbojevic-Stankovic J., et al. Predicting multiple organ failure in patients with severe trauma. Can J Surg 2008, 51:97-102.
16. Gebhard F., Pfetsch H., Steinbach G., et al. Is interleukin-6 an early marker of injury severity following major trauma in humans?. Arch Surg 2000, 135:291-295.
17. Stensballe J., Christiansen M., Tonnesen E., et al. The early IL-6 and IL-10 response in trauma is correlated with injury severity and mortality. Acta Anaesthesiol Scand 2009, 53:515-521.
18. Giannoudis P.V., Hildebrand F., Pape H.C. Inflammatory serum markers in patients with multiple trauma. Can they predict outcome?. J Bone Joint Surg Br 2004, 86:313-323.
19. Mimasaka S., Hashiyada M., Nata M., et al. Correlation between serum IL-6 levels and death: usefulness in diagnosis of " traumatic shock?" Tohoku J Exp Med 2001, 193:319-324.
20. Johannes F., Marcus M., Jochen K., et al. Circulating inflammatory and metabolic parameters to predict organ failure after multiple trauma. Eur J Trauma 2002, V28:333-339.
21. Woiciechowsky C., Schoning B., Cobanov J., et al. Early IL-6 plasma concentrations correlate with severity of brain injury and pneumonia in brain-injured patients. J Trauma 2002, 52:339-345.
22. Heizmann O., Koeller M., Muhr G., et al. Th1- and Th2-type cytokines in plasma after major trauma. J Trauma 2008, 65:1374-1378.
23. Tschoeke S.K., Ertel W. Immunoparalysis after multiple trauma. Injury 2007, 38:1346-1357.
24. Couper K.N., Blount D.G., Riley E.M. IL-10: the master regulator of immunity to infection. J Immunol 2008, 180:5771-5777.
25. Ertel W., Morrison M.H., Ayala A., et al. Blockade of prostaglandin production increases cachectin synthesis and prevents depression of macrophage functions after hemorrhagic shock. Ann Surg 1991, 213:265-271.
26. Matzinger P. Friendly and dangerous signals: is the tissue in control?. Nat Immunol 2007, 8:11-13.
27. Marshall J. Both the disposition and the means of cure: 'severe SIRS', 'sterile shock', and the ongoing challenge of description. Crit Care Med 1997, 25:1765-1766.
28. Moore F.A., Moore E.E. Evolving concepts in the pathogenesis of postinjury multiple organ failure. Surg Clin North Am 1995, 75:257-277.
29. Bianchi M.E. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007, 81:1-5.
30. Oppenheim J.J., Yang D. Alarmins: chemotactic activators of immune response. Curr Opin Immunol 2005, 17:359-365.
31. Klune J.R., Dhupar R., Cardinal J., et al. HMGB1: endogenous danger signaling. Mol Med 2008, 14:476-484.
32. Fink M.P. Bench-to-bedside review: high-mobility group box 1 and critical illness. Crit Care 2007, 11:229.
33. Gibot S., Massin F., Cravoisy A., et al. High-mobility group box 1 protein plasma concentrations during septic shock. Intensive Care Med 2007, 33:1347-1353.
34. Cohen M.J., Brohi K., Calfee C.S., et al. Early release of high mobility group box nuclear protein 1 after severe trauma in humans: role of injury severity and tissue hypoperfusion. Crit Care 2009, 13:R174.
35. Sunden-Cullberg J., Norrby-Teglund A., Rouhiainen A., et al. Persistent elevation of high mobility group box-1 potein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 2005, 33:564-573.
36. Wang H., Bloom O., Zhang M., et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285:248-251.
37. Ombrellino M., Wang H., Ajemian M.S., et al. Increased serum concentrations of high-mobility group protein 1 in hemorrhagic shock. Lancet 1999, 354:1446-1447.
38. Yang R., Harada N., Mollen K.P., et al. Anti-HMGB1 neutralizing antibody ameliorates gut barrier dysfunction and improves survival after hemorrhagic shock. Mol Med 2006, 12:104-114.
39. Kim J.Y., Park J.S., Strassheim D., et al. HMGB1 contributes to the development of acute lung injury after hemorrhage. Am J Physiol Lung Cell Mol Physiol 2005, 288:958-965.
40. Guo F., Shi Y., Xu H., et al. High mobility group box 1 as a mediator of endotoxin administration after hemorrhagic shock-primed lung injury. Braz J Med Biol Res 2009, 42:804-811.
41. Mueller B., White J.C., Nylen E.S., et al. Ubiquitous expression of the calcitonin-1 gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab 2001, 56:396-404.
42. Clec'h C., Ferriere F., Karoubi P., et al. Diagnostic and prognostic value of procalcitonin in patients with septic shock. Crit Care Med 2004, 32:1166-1169.
43. Uzzan B., Cohen R., Nicolas P., et al. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 2006, 34:1996-2003.
44. Assicot M., Gendrel D., Carsin H., et al. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993, 341:515-518.
45. Dahaba A.A., Metzler H. Procalcitonin's role in the sepsis cascade. Is procalcitonin a sepsis marker or mediator?. Minerva Anestesiol 2009, 75:447-452.
46. Reith H.B., Mittelkowtter U., Debus E.S., et al. Procalcitonin in early detection of postoperative complications. Dig Surg 1998, 15:260-265.
47. Dahaba A.A., Hagara B., Fall A., et al. Procalcitonin for early prediction of survival outcome in postoperative critically ill patients with severe sepsis. Br J Anaesth 2006, 97:503-508.
48. Mokart D., Merlin M., Sannini A., et al. Procalcitonin, interleukin 6 and systemic inflammatory response syndrome (SIRS): early markers of postoperative sepsis after major surgery. Br J Anaesth 2005, 94:767-773.
49. Schroeder J., Staubach K.H., Zabel P., et al. Procalcitonin as a marker of severity in septic shock. Langenbecks Arch Surg 1999, 384:33-38.
50. Vincent J.L., de Mendonca A., Cantraine F., et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on " sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med 1998, 26:1793-1800.
51. Castelli G.P., Pognani C., Cita M., et al. Procalcitonin as a prognostic and diagnostic tool for septic complications after major trauma. Crit Care Med 2009, 37:1845-1849.
52. Meisner M., Adina H., Schmidt J. Correlation of procalcitonin and C-reactive protein to inflammation, complications, and outcome during the intensive care unit course of multiple-trauma patients. Crit Care 2006, 10:R1.
53. Balci C., Sivaci R., Akbulut G., et al. Procalcitonin level as an early marker in patients with multiple trauma under intensive care. J Int Med Res 2009, 37:1709-1717.
54. Szalai A.J., Briles D.E., Volnakis J.E. Role of complement in C-reactive-protein-mediated protection of mice from Streptococcus pneumoniae. Infect Immun 1996, 64:4850-4853.
55. Biffl W.L., Moore E.E., Moore F.A., et al. Interleukin-6 in the injured patient. Marker of injury or mediator of inflammation?. Ann Surg 1996, 224:647-664.
56. Herzum I., Renz H. Inflammatory markers in SIRS, sepsis and septic shock. Curr Med Chem 2008, 15:581-587.
57. Hensler T., Sauerland S., Lefering R., et al. The clinical value of procalcitonin and neopterin in predicting sepsis and organ failure after major trauma. Shock 2003, 20:420-426.
58. Wanner G.A., Keel M., Steckholzer U., et al. Relationship between procalcitonin plasma levels and severity of injury, sepsis, organ failure, and mortality in injured patients. Crit Care Med 2000, 28:950-957.
59. Redl H., Schlag G., Togel E., et al. Procalcitonin release patterns in a baboon model of trauma and sepsis: relationship to cytokines and neopterin. Crit Care Med 2000, 28:3659-3663.
60. Maier M., Wutzler S., Lehnert M., et al. Serum procalcitonin levels in patients with multiple injuries including visceral trauma. J Trauma 2009, 66:243-249.
61. Sauerland S., Hensler T., Bouillon B., et al. Plasma levels of procalcitonin and neopterin in multiple trauma patients with or without brain injury. J Neurotrauma 2003, 10:953-960.
62. Rush B.F., Sori A.J., Murphy T.F., et al. Endotoxemia and bacteremia during hemorrhagic shock. The link between trauma and sepsis. J Trauma 1988, 207:549-554.
63. Deitch E.A. Bacterial translocation of the gut flora. J Trauma 1990, 30:S184-S189.
64. Deitch E.A., Xu D., Franko L., et al. Evidence favoring the role of the gut as a cytokine-generating organ in rats subjected to hemorrhagic shock. Shock 1994, 1:141-145.
65. Schmiegel W., Burchert M., Kalthoff H., et al. Immunochemical characterization and quantitative distribution of pancreatic stone protein in sera and pancreatic secretions in pancreatic disorders. Gastroenterology 1990, 99:1421-1430.
66. Dusetti N.J., Ortiz E.M., Mallo G.C., et al. Pancreatitis-associated protein I (PAP I), an acute phase protein induced by cytokines. Identification of two functional interleukin-6 response elements in the rat PAP I promoter region. J Biol Chem 1995, 330:129-132.
67. Keel M., Harter L., Reding T., et al. Pancreatic stone protein is highly increased during posttraumatic sepsis and activates neutrophil granulocytes. Crit Care Med 2009, 37:1642-1648.
68. Becchi C., Pillozzi S., Fabbri L.P., et al. The increase of endothelial progenitor cells in the peripheral blood: a new parameter for detecting onset and severity of sepsis. Int J Immunopathol Pharmacol 2008, 21:697-705.
69. Livingston D.H., Anjaria D., Wu J., et al. Bone marrow failure following severe injury in humans. Ann Surg 2003, 238:748-753.
70. + regulatory T cells and plasma levels of soluble CD25. Tohoku J Exp Med 2008, 216:61-68.
71. Ni Choileain N., MacConmara M., Zang Y., et al. Enhanced regulatory T cell activity is an element of the host response to injury. J Immunol 2006, 176:225-236.
72. - regulatory T cells and inflammatory response and outcome during shock states. Crit Care 2010, 14:R19.
73. Suttner S.W., Boldt J. Natriuretic peptide system: physiology and clinical utility. Curr Opin Crit Care 2004, 10:336-341.
74. Barr C.S., Rhodes P., Struthers A.D. C-type natriuretic peptide. Peptides 1996, 17:1243-1251.
75. Nazario B., Hu R.M., Komatsu Y., et al. Cytokine induced C-type natriuretic peptide (CNP) secretion from vascular endothelium cells - evidence for CNP as a novel autocrine/paracrine regulator from endothelial cells. Endocrinology 1993, 133:3038-3041.
76. Bahrami S., Pelink L., Khadem A., et al. Circulating NT-proCNP predicts sepsis in multiple traumatized patients without brain injury. Crit Care Med 2010, 38:161-166.
77. Osborn T.M., Tracy J.K., Dunne J.R., et al. Epidemiology of sepsis in patients with traumatic injury. Crit Care Med 2004, 32:2234-2240.
78. Pierrakos C., Vincent J.L. Sepsis biomarkers: a review. Crit Care 2010, 14:R15.